AstraZeneca's CEO says AI hasn't produced a single new drug candidate yet, but insists it won't cost jobs either

Started by MJF_Fan, Yesterday at 01:21 PM

Previous topic - Next topic

0 Members and 1 Guest are viewing this topic.

Topic: AstraZeneca's CEO says AI hasn't produced a single new drug candidate yet, but insists it won't cost jobs either   Views(Read 43 times)
Active members in this topic:
MJF_Fan(1)

MJF_Fan

AstraZeneca CEO Pascal Soriot said this week that the company's use of AI in drug design and development has not yet yielded any clinical stage drug candidates, a notably candid admission given how heavily the pharmaceutical industry has leaned into AI hype over the past few years. At the same time, Soriot pushed back firmly on the idea that AI threatens jobs in his industry, telling reporters that calling AI a job killer is fake news, and that he expects it will make people faster and smarter rather than triggering a big reduction in headcount

Soriot has previously detailed concrete ways AI is already changing the company's work even without a clinical candidate to show for it yet, describing an AI agent developed with partner Tempus AI that combines clinical and laboratory data to predict the probability of a Phase 3 trial succeeding before the company commits hundreds of millions of dollars to running it. He's also said AI helps identify new drug targets and optimize a molecule's design to remove likely side effects earlier in development, framing the value of AI in his industry explicitly as productivity improvement, letting the company design medicines faster and smarter rather than replacing the scientists doing that work

The comments land at a moment when investors across every industry are increasingly questioning whether massive AI spending is producing real returns, and pharmaceutical AI specifically has faced skepticism given how long drug development timelines run and how expensive Phase 3 failures are. Soriot's framing, real productivity gains already visible in decision making and risk reduction, but no finished product yet and no expectation of major layoffs, offers a notably measured middle ground between AI hype and AI skepticism from a company with genuine skin in the game rather than a vendor trying to sell AI tools

Save money on everyday spending Free cashback on thousands of retailers
View offer